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Materials and method. We analyze 133 patients staged IIa–IIIc. 59 pts in VP, 74 pts in SP. Groups were well balanced. There were
less stages II (9% vs. 29%) and stages III (34% VS. 35%) in VP than in SP p<0.0001. All pts were treated to a total dose of 50.4Gy and
concomitant ﬂuoropyrimidine-based chemotherapy. A dedicated colorectal team of surgeons underwent all MRS in our hospital.
We analyze pts for overall survival (OS) and disease free survival (DFS).
Results. Median follow up was 3.25 years (0.25–9.28) OS at 2 and 5 years: 82%, 74%. OS cancer-speciﬁc (CA) at 2 and 5 years: 90%,
78%. Mean DFS global was: 7.05 years (IC 95%: 6.31–7.79). Mean DFS local relapse was: 8.17 years (IC 95: 7.59–8.75). Mean OS VP
vs. SP was 3.68 vs. 7.34 years hazard ratio (HR) = 1.068, p=ns. OS (CA) VP vs. SP 3.9 vs. 7.9 years, HR=1.07, p=ns. Mean DFS VP
vs. SP 3.7 vs. 6.83, HR=1.49, p=ns. Mean DFS (local relapse) VP vs. SP 3.88 vs. 8.08 years HR=1.26, p=ns. Pts whose pathological
stage was higher (PG) than clinical stage had worse OS survival than those with non-response (NR) or any response (AR): PG=5.14
years vs. NR=6.2 vs. AR=7.55, p<0.05.
Conclusion. Patients included in VP suffer from more advanced disease than PS, yet their OS and DFS were equivalent.
http://dx.doi.org/10.1016/j.rpor.2013.03.212
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Introduction and objectives. In 2011, following the preliminary results of the CROSS trial, published in late 2010 our unit esopha-
gogastric cancer treatment decided to start with this promising protocol. In our case we intend to ﬁnd out if you may get better
results than the previous protocol used in our center RTCT including cisplatin and 5FU-in 2nd place if possible with a lower
mortality.
Material and methods. We included 10 patients where it has established the possibility of preoperative treatment as inclusion
exclusion criteria of the protocol, respecting the guidelines of dose and schedule recommended.
Results. The 50% of patients had TNM stage, T3N1M0 while the remaining 50% were T3N0M0. The predominant histology was
adenocarcinoma of the lower esophageous-cardia in 90%.Mean agewas 58 years (range 35–75 years) 90% of the patients improved
from the dysphagia symptoms, not requiring entrance feeding tube or in any case admittance at hospital. Surgery was performed
at 6 weeks CTRT ﬁnish. Presented a low rate of complications: only 1 patient (10%) had wound dehiscence. Another patient
had hypoxemia secondary to bilateral basal atelectasis (10%). 0% mortality. In 100% of patients after CTRT understaging was
objectiﬁed. The majority of patients had R0 resection. And pathological stage. Most frequent was yPT1a-bN0M0 The results in
terms of survival are not mature
Conclusions. In principle it is a secure protocol agile and very effective, facilitating surgery with level low morbidity associated.
http://dx.doi.org/10.1016/j.rpor.2013.03.213
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Objective. A signiﬁcant decrease in lymph node yield after preoperative radio-chemotherapy for rectal cancer compared with
surgery upfront has been described. The goal of this investigation is to determine the prognostic value of the number of lymph
nodes retrieved in patients with LARC treated with preoperative RCT. We also investigated the prognostic value of the local and
regional response after RCT.
Material and methods. Eligible patients presented a diagnosis of proven rectal Adenocarcinoma, stage T2 to T4 and/or N1 to N2.
Patients were treated with pelvic RT (46–50Gy in 2Gy fractions), and 5Fu iv in continuous infusion (225mg/m2) or Capecitabine
(825mg/m2) during RT, followed by TME in 6 weeks after RT-CT. Number of nodes retrieved was analyzed and association with
clinicopathological characteristics were studied. Univariant and multivariant survival analysis were performed.
Results. The mean number of nodes identiﬁed in the surgical specimen was 10 with a range from 0 to 28. 23% of the patients had
at least 7 nodes retrieved, 50% of the patients had at least 10 nodes, 35% at least 12 nodes and 24% at least 14 nodes retrieved. A
signiﬁcant correlation (p=0.001) was found between the number of lymph nodes retrieved and number of lymph nodes affected
(Pearson coefﬁcient 0.37). Retrieval of at least 10 lymph nodes and yT response were independent prognostic factors (p=0.03 and
p=0.005 respectively).
